Active Ingredient History

NOW
  • Now
Bermekimab is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March¬†2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data
human igg1 monoclonal antibody specific for human interleukin-1 alpha

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue